ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the quarter ended June 30, 2014 on Wednesday, August 13, 2014.
InSite Vision management will host a conference call that day beginning at 4:30 p.m. ET/1:30 p.m. PT to discuss second quarter 2014 financial results and to review recent accomplishments and upcoming milestones. Investors will be invited to ask questions following management’s prepared remarks.
Analysts and investors can participate in the conference call by dialing 888-680-0892 for domestic callers and 617-213-4858 for international callers using the pass code 93862510. Interested parties are encouraged to pre-register to avoid delays at https://www.theconferencingservice.com/prereg/key.process?key=PLP4LYTUL. A telephone replay will be available for two weeks following the conclusion of the call by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers using the pass code 63246334.
The conference call will also be webcast and available on the Investor Relations page of the company's website at www.insitevision.com. Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required.
A press release detailing second quarter 2014 financial results will be posted to the company's website and furnished to the Securities and Exchange Commission on a Form 8-K.
About InSite Vision
InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite® platform technologies. The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.
The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Akorn Inc.; and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International. InSite Vision is also advancing AzaSite Plus™, a novel ophthalmic therapeutics through Phase 3 clinical studies for the treatment of eye infections, and is preparing two new drug applications (NDA) for the commercial approval by the U.S. Food & Drug Administration (FDA): BromSite™ for the treatment of inflammation and prevention of pain associated with cataract surgery and DexaSite™ for the treatment of blepharitis. For further information on InSite Vision, please visit www.insitevision.com.
AzaSite® and DuraSite® are registered trademarks of InSite Vision Incorporated.
AzaSite Plus™, BromSite™ and DexaSite™ are trademarks of InSite Vision Incorporated.
BESIVANCE® is a registered trademark of Bausch + Lomb Incorporated.